Home » FDA Debars Ohio Oncologist for Misbranded Drugs
FDA Debars Ohio Oncologist for Misbranded Drugs
January 8, 2019
The FDA issued an order to debar an Ohio oncologist from purchasing and receiving unapproved drugs from a Canadian distributor.
Ranjan Bhandari was convicted of a misdemeanor in 2013 for buying misbranded prescription drugs between 2006 and 2008, including Zometa (zoledronic acid), a high blood calcium treatment; Gemzar (gemcitabine), an oncology treatment; and Aranesp (darbepoetin alfa), a bone marrow stimulant.
Bhandari is debarred for three years from providing services to any person with an approved or pending drug product application.
Upcoming Events
-
21Oct